actin related protein T2Genealiases: ARPM2 · ARPT2 · Arp-T2 · HARPM2
Q-omics provides the consensus-scored ACTRT2 profile across patient tissues and cancer cell-line models. ACTRT2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ACTRT2 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, ACTRT2 RNA expression shows 3,679 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, and STAD as cancer lineages where ACTRT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTRT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTRT2 survival associations across molecular data types. ACTRT2 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTRT2 RNA expression–survival associations across cancer types. High ACTRT2 expression shows unfavorable associations in KICH, KIRC, CHOL, BRCA and UCEC, but favorable associations in HNSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ACTRT2 RNA expression.
This table summarizes ACTRT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for ACTRT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTRT2 shows higher tumor expression in STAD. The STAD box plot shows higher ACTRT2 RNA expression in tumor versus normal tissue (log2 FC = +0.007, t-test p = .041).
This table shows molecular features associated with ACTRT2 in patient tissues and cancer cell lines. In patient samples, ACTRT2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ACTRT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
